LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Listă Acțiuni・Natera Inc

Natera Inc

Închisă

SectorSănătate

212.74 -2.28

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

210.75

Maxim

217.71

Indicatori cheie
By Trading Economics
Venit	-132M -85M
Vânzări	31M 697M
EPS	-0.6
Marjă de profit	-12.214
Angajați	6,135
EBITDA	-38M -73M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+19.81% upside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	1.1B 31B
Deschiderea anterioară	215.02
Închiderea anterioară	212.74

Sentimentul știrilor

By Acuity

37%

63%

104 / 344 Clasament în Healthcare

Natera Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 iun. 2026, 20:30 UTC

Câștiguri

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 iun. 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 iun. 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 iun. 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 iun. 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 iun. 2026, 23:01 UTC

Achiziții, Fuziuni, Preluări

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 iun. 2026, 23:01 UTC

Achiziții, Fuziuni, Preluări

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 iun. 2026, 23:00 UTC

Achiziții, Fuziuni, Preluări

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 iun. 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 iun. 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 iun. 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 iun. 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 iun. 2026, 21:00 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 iun. 2026, 20:46 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:38 UTC

Câștiguri

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 iun. 2026, 20:21 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:12 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Product Rev $594M

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Loss $177M >PANW

Comparație

Modificare preț

Natera Inc Așteptări

Obiectiv de preț

By TipRanks

19.81% sus

Prognoză pe 12 luni

Medie 262.15 USD 19.81%

Maxim 300 USD

Minim 220 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNatera Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 14 analiști care au acordat evaluări ale acțiunilor Natera Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

104 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.